DATE/TIME
September 27, 09:30 – 10:00 AM EST
TITLE
Bridging the Divide: Understanding Contrasting Approaches in Drug Development
SPEAKER
Ray Forslund, Ph.D., MBA
SVP of Pharmaceutical Development
Syner-G BioPharma Group
ABSTRACT
Drug development is a multifaceted journey requiring substantial investments of time, resources, and expertise. Biotech’s and large pharma entities are integral to ushering novel therapies from conception to commercialization. However, their approaches diverge significantly due to varying organizational structures, financial capacities, and risk tolerance. These discrepancies often pose challenges when collaboration is sought. Additionally, differences extend beyond clinical development to CMC timelines and development, emphasizing the need for a holistic understanding of the industry landscape’s disparities. This article comprehensively analyzes the divergent paths undertaken by small biotech and large pharma companies in drug development.
BIO
Ray has over fifteen years of experience in the industry working for both pharmaceutical and CRO/CMO companies. As a member of the Syner-G Executive Leadership team, he leads the CMC Development and Project Management business unit. His team is responsible for providing scientific solutions for drug development programs including identifying and managing CRO/CMO/CDMOs for Syner-G’s clients to support drug substance, drug product, and analytical development activities in biologics, small molecules, and peptides.
